2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P10785
    Iturin A-2 83785-07-3 98%
    Iturin A-2 is a cyclic lipopeptide discovered in B. subtilis and exhibits inhibitory activity against the plant pathogenic fungus P. expansum (MIC = 8 µg/disk). Iturin A-2 is cytotoxic to MCF-7 and BT474 breast cancer cells, as well as HeLa cervical cancer cells, with IC50 values of 66.81, 95.04, and 77.5 µg/mL, respectively. In greenhouse studies, Iturin A-2 at concentrations of 100 and 300 mg/kg Iturin A-2 reduces the lesion area of southern corn leaf blight caused by B. maydis, and in field studies, concentrations of 300 and 500 mg/kg Iturin A-2 reduce the incidence of the disease. Iturin A-2 (12.5 µg/mL) inhibits cell division, but not nuclear division, in isolated fertilized starfish eggs.
    Iturin A-2
  • HY-P10795
    NK-2 280138-31-0 98%
    NK-2 (Antibiotic NK 2), a shortened linear amphipathic NK-Lysin analog (comprising residues 39 to 65 of NK-lysin), is an antimicrobial peptide that exhibits potent activities against trypanosoma cruzi, Candida albicans, gram-positive and gram-negative bacteria. NK-2 can kill trypanosomes residing inside the human glioblastoma cell line 86HG39, left the host cells apparently unharmed.
    NK-2
  • HY-P10801
    mC46 peptide 98%
    mC46 (C46) peptide is a membrane-associated fusion peptide inhibitor. mC46 peptide potently inhibits HIV-1 replication and entry. mC46 also inhibits CCR5-tropic, CXCR4-tropic, and dual-tropic HIVs, SIV, and SHIV.
    mC46 peptide
  • HY-P10802
    ER-DRI 98%
    ER-DRI is a potent peptide inhibitor that tagets EV-A71. ER-DRI directly bounds to 3A and specifically abrogates viral suppressor of RNAi activity, which unlocked the antiviral RNAi response that is suppressed by 3A. ER-DRI also potently inhibits another enterovirus, Coxsackievirus-A16, dependently of RNAi.
    ER-DRI
  • HY-P10803
    FLDKFNHEAEDLFYQSSL 98%
    FLDKFNHEAEDLFYQSSL is an 18-residue peptide that binds to SARS-CoV-2 receptor-binding domain (RBD). FLDKFNHEAEDLFYQSSL inhibits the entry of SARS-Cov-2. FLDKFNHEAEDLFYQSSL also interacts with binding residues (Leu455, Phe456, Ala475 and Gln493).
    FLDKFNHEAEDLFYQSSL
  • HY-P10804
    PIH 98%
    PIH is an antiviral peptide that effectively inhibits the HR1/HR2-mediated membrane fusion between MERS-CoV and host cells, with an IC50 of 1.171 μM. By forming a complex with gold nanorods (AuNRs), the antiviral efficacy of PIH can be further enhanced by 10-fold.
    PIH
  • HY-P10805
    Capsid assembly inhibitor 865292-94-0 98%
    Capsid assembly inhibitor is a 12-mer peptide that binds the capsid (CA) domain of Gag and inhibits assembly of immature- and mature-like HIV-1 capsid particles in vitro.
    Capsid assembly inhibitor
  • HY-P10814
    MciZ (B. subtilis) 98%
    MciZ (B. subtilis), a 40-amino-acid peptide, inhibits the GTPase activity of FtsZ that prevents inappropriate Z-ring formation during sporulation.
    MciZ (B. subtilis)
  • HY-P10820
    N36Mut(e,g) 98%
    N36Mut(e,g) is a gp41-targeted HIV fusion peptide inhibitor. N36Mut(e,g) acts by disrupting the homotrimeric coiled-coil of N-terminal helices in the pre-hairpin intermediate to form heterotrimers.
    N36Mut(e,g)
  • HY-P10828
    MAPI 1260620-30-1 98%
    MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection.
    MAPI
  • HY-P10829
    MLH40 98%
    MLH40 is a peptide inhibitor with activity against Dengue virus (DENV) infection, which is found in the conserved ectodomain region of DENV membrane protein. MLH40 inhibits DENV through its N-terminal loop interaction with DENV envelope protein and altering the dimer conformation.
    MLH40
  • HY-P10830
    AT1R epitope 161146-12-9 98%
    AT1R epitope (iCF10), a heptapeptide, is a competitive cCF10 (a peptide pheromone) inhibitor.
    AT1R epitope
  • HY-P10834
    NYAD-13 1042980-96-0 98%
    NYAD-13 exhibits antiviral activity against HIV-1 IIIB, but it also possesses significant cytotoxicity.
    NYAD-13
  • HY-P10845
    KRL74 2423969-43-9 98%
    KRL74 is a cyclic peptide inhibitor for interaction between the p6 domain of the HIV Gag protein and the UEV domain of the human TSG101 protein(p6/UEV) with an IC50 of 5.44 μM and a Kd of 11.9 μM. KRL74 inhibits the budding process of HIV from host cells with an IC50 of 2 μM in virus-like particle (VLP) budding assay.
    KRL74
  • HY-P10855
    S1b3inL1 3027437-21-1 98%
    S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity.
    S1b3inL1
  • HY-P10858
    UCI-1 98%
    UCI-1 is a SARS-CoV-2 main protease (Mpro) cyclic peptide inhibitor with an IC50 of 160 μM. UCI-1 shows no obvious cytotoxicity at the concentration of inhibiting Mpro. UCI-1 can be used in the study of anti-COVID-19 drugs.
    UCI-1
  • HY-P10868
    Pegtarazimod 2056232-82-5 98%
    Pegtarazimod (RLS-0071) is a dual-target anti-inflammatory peptide that exerts its effects by simultaneously regulating the complement system and neutrophil-associated inflammatory pathways. Pegtarazimod reduces ROS production both in vitro and in vivo, and decreases the level of neutrophil elastase, a marker of neutrophil extracellular traps (NETs), in vivo, thereby alleviating inflammatory responses. Pegtarazimod significantly improves the survival rate of mice in multiple in vivo models of acute graft-versus-host disease (aGVHD). Pegtarazimod inhibits the activation of the C1 complex, reduces the herpes zoster-like spread of herpes simplex virus type 1 skin infection, and improves the survival rate of infected mice. Pegtarazimod can be used in research related to acute graft-versus-host disease, acute pulmonary diseases, and skin herpes simplex virus type 1 infection.
    Pegtarazimod
  • HY-P10871
    cTEV6-2 98%
    cTEV6-2 binds to the cysteine residue (C151) of tobacco etch virus protease (TEV protease), and covalently inhibits TEV protease with an IC50 of 81.7 nM.
    cTEV6-2
  • HY-P10872
    P315V3 98%
    P315V3 is an pan inhibitor for coronavirus, that inhibits SARS-CoV-2 prototypePT, Delta, BA.1 and BA.4 strain with IC50s of 10.9, 8.9, 8.6, and 2.7 nM. P315V3 exhibits cytotoxicity in Vero cell with CC50 of 4.3 μM. P315V3 exhibits anti-infectious efficacy in mouse models.
    P315V3
  • HY-P10874
    SMR efflux inhibitor 98%
    SMR efflux inhibitor targets the small multidrug resistance (SMR) efflux pump, blocks the interaction of TM4-TM4, and exhibits board-spectrum antibacterial activity.
    SMR efflux inhibitor
Cat. No. Product Name / Synonyms Application Reactivity